{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:16:17Z","timestamp":1785521777363,"version":"3.56.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41417-026-01016-9","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:35:16Z","timestamp":1773916516000},"page":"673-684","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gracillin overcomes osimertinib resistance in NSCLC via dual inhibition of EGFR and Mcl-1"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-8269","authenticated-orcid":false,"given":"Jinzhuang","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuecheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangze","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruirui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7267-6494","authenticated-orcid":false,"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"1016_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/cac2.12359","volume":"42","author":"P Chen","year":"2022","unstructured":"Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun. 2022;42:937\u201370.","journal-title":"Cancer Commun"},{"key":"1016_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115891","volume":"169","author":"Y Li","year":"2023","unstructured":"Li Y, Yan B, He S. Advances and challenges in the treatment of lung cancer. Biomed Pharmacother. 2023;169:115891.","journal-title":"Biomed Pharmacother"},{"key":"1016_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","volume":"404","author":"ML Meyer","year":"2024","unstructured":"Meyer ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, J\u00e4nne PA, Peters S, et al. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet. 2024;404:803\u201322.","journal-title":"Lancet"},{"key":"1016_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-pathol-011110-130206","volume":"6","author":"G da Cunha Santos","year":"2011","unstructured":"da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol. 2011;6:49\u201369.","journal-title":"Annu Rev Pathol"},{"key":"1016_CR5","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","volume":"29","author":"D Westover","year":"2018","unstructured":"Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29:i10\u2013i9.","journal-title":"Ann Oncol"},{"key":"1016_CR6","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jtho.2024.12.012","volume":"20","author":"D Tavernari","year":"2025","unstructured":"Tavernari D, Borgeaud M, Liu X, Parikh K, Le X, Ciriello G, et al. Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC: A Brief Report. J Thorac Oncol. 2025;20:500\u20136.","journal-title":"J Thorac Oncol"},{"key":"1016_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, et al. Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22:249\u201374.","journal-title":"J Natl Compr Canc Netw"},{"key":"1016_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","volume":"15","author":"K Fu","year":"2022","unstructured":"Fu K, Xie F, Wang F, Fu L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 2022;15:173.","journal-title":"J Hematol Oncol"},{"key":"1016_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/cdd.2017.186","volume":"25","author":"J Kale","year":"2018","unstructured":"Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 2018;25:65\u201380.","journal-title":"Cell Death Differ"},{"key":"1016_CR10","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41580-023-00629-4","volume":"24","author":"PE Czabotar","year":"2023","unstructured":"Czabotar PE, Garcia-Saez AJ. Mechanisms of BCL-2 family proteins in mitochondrial apoptosis. Nat Rev Mol Cell Biol. 2023;24:732\u201348.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1016_CR11","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/ncb2488","volume":"14","author":"RM Perciavalle","year":"2012","unstructured":"Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M, et al. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol. 2012;14:575\u201383.","journal-title":"Nat Cell Biol"},{"key":"1016_CR12","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.molcel.2024.02.035","volume":"84","author":"T Wright","year":"2024","unstructured":"Wright T, Turnis ME, Grace CR, Li X, Brakefield LA, Wang YD, et al. Anti-apoptotic MCL-1 promotes long-chain fatty acid oxidation through interaction with ACSL1. Mol Cell. 2024;84:1338\u201353.e8.","journal-title":"Mol Cell"},{"key":"1016_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","volume":"14","author":"H Wang","year":"2021","unstructured":"Wang H, Guo M, Wei H, Chen Y. Targeting MCL-1 in cancer: current status and perspectives. J Hematol Oncol. 2021;14:67.","journal-title":"J Hematol Oncol"},{"key":"1016_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06155-7","volume":"14","author":"L Zhang","year":"2023","unstructured":"Zhang L, Dong Y, Zhang L, Wang M, Zhou Y, Jia K, et al. Mitochondrial IRG1 traps MCL-1 to induce hepatocyte apoptosis and promote carcinogenesis. Cell Death Dis. 2023;14:625.","journal-title":"Cell Death Dis"},{"key":"1016_CR15","doi-asserted-by":"publisher","first-page":"579","DOI":"10.7150\/ijbs.29775","volume":"15","author":"Y Liu","year":"2019","unstructured":"Liu Y, Lei P, Qiao H, Sun K, Lu X, Bao F, et al. miR-9 Enhances the Chemosensitivity of AML Cells to Daunorubicin by Targeting the EIF5A2\/MCL-1 Axis. Int J Biol Sci. 2019;15:579\u201386.","journal-title":"Int J Biol Sci"},{"key":"1016_CR16","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1039\/C4NP00064A","volume":"31","author":"MS Butler","year":"2014","unstructured":"Butler MS, Robertson AA, Cooper MA. Natural product and natural product derived drugs in clinical trials. Nat Prod Rep. 2014;31:1612\u201361.","journal-title":"Nat Prod Rep"},{"key":"1016_CR17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","volume":"20","author":"AG Atanasov","year":"2021","unstructured":"Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021;20:200\u201316.","journal-title":"Nat Rev Drug Discov"},{"key":"1016_CR18","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.7150\/ijbs.69116","volume":"18","author":"Z Gao","year":"2022","unstructured":"Gao Z, Yi W, Tang J, Sun Y, Huang J, Lan T, et al. Urolithin A protects against acetaminophen-induced liver injury in mice via sustained activation of Nrf2. Int J Biol Sci. 2022;18:2146\u201362.","journal-title":"Int J Biol Sci"},{"key":"1016_CR19","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.7150\/ijbs.77720","volume":"19","author":"X Wang","year":"2023","unstructured":"Wang X, Li J, Chen R, Li T, Chen M. Active Ingredients from Chinese Medicine for Combination Cancer Therapy. Int J Biol Sci. 2023;19:3499\u2013525.","journal-title":"Int J Biol Sci"},{"key":"1016_CR20","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.7150\/ijbs.113709","volume":"21","author":"Q Wang","year":"2025","unstructured":"Wang Q, Xue F, Assaraf YG, Lin Y. Harnessing Natural Products to Surmount Drug Resistance in Gastric Cancer: Mechanisms and Therapeutic Perspectives. Int J Biol Sci. 2025;21:4604\u201328.","journal-title":"Int J Biol Sci"},{"key":"1016_CR21","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1039\/D2NP00091A","volume":"40","author":"BK Mize","year":"2023","unstructured":"Mize BK, Salvi A, Ren Y, Burdette JE, Fuchs JR. Discovery and development of botanical natural products and their analogues as therapeutics for ovarian cancer. Nat Prod Rep. 2023;40:1250\u201370.","journal-title":"Nat Prod Rep"},{"key":"1016_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.116704","volume":"316","author":"M Xie","year":"2023","unstructured":"Xie M, Yang L, Cheng J, Qu H, Gu Y, Ding C, et al. Gracillin relieves pulmonary fibrosis by suppressing the STAT3 axis. J Ethnopharmacol. 2023;316:116704.","journal-title":"J Ethnopharmacol"},{"key":"1016_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.31083\/ph.2015.4742","volume":"70","author":"CR Chen","year":"2015","unstructured":"Chen CR, Zhang J, Wu KW, Liu PY, Wang SJ, Chen DY, et al. Gracillin induces apoptosis in HL60 human leukemic cell line via oxidative stress and cell cycle arrest of G1. Pharmazie. 2015;70:199\u2013204.","journal-title":"Pharmazie"},{"key":"1016_CR24","doi-asserted-by":"crossref","unstructured":"Jegal J, Park NJ, Jo BG, Bong SK, Jegal H, Yang MH, et al. Anti-Atopic Properties of Gracillin Isolated from Dioscorea quinqueloba on 2,4-Dinitrochlorobenzene-Induced Skin Lesions in Mice. Nutrients. 2018;10:1205.","DOI":"10.3390\/nu10091205"},{"key":"1016_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.202300847","volume":"20","author":"MS Bhuia","year":"2023","unstructured":"Bhuia MS, Chowdhury R, Sonia FA, Kamli H, Shaikh A, El-Nashar HAS, et al. Anticancer Potential of the Plant-Derived Saponin Gracillin: A Comprehensive Review of Mechanistic Approaches. Chem Biodivers. 2023;20:e202300847.","journal-title":"Chem Biodivers"},{"key":"1016_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.154526","volume":"108","author":"JK Li","year":"2023","unstructured":"Li JK, Zhu PL, Wang Y, Jiang XL, Zhang Z, Zhang Z, et al. Gracillin exerts anti-melanoma effects in vitro and in vivo: role of DNA damage, apoptosis and autophagy. Phytomedicine. 2023;108:154526.","journal-title":"Phytomedicine"},{"key":"1016_CR27","doi-asserted-by":"crossref","unstructured":"Su JX, Zhou HX, Zhang ZJ, Zhou XF, Zou QM, Li SJ, et al. Gracillin suppresses cancer progression through inducing Merlin\/LATS protein-protein interaction and activating Hippo signaling pathway. Acta Pharmacol Sin. 2025;46:2016\u201328.","DOI":"10.1038\/s41401-025-01514-w"},{"key":"1016_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2041-z","volume":"10","author":"HY Min","year":"2019","unstructured":"Min HY, Jang HJ, Park KH, Hyun SY, Park SJ, Kim JH, et al. The natural compound gracillin exerts potent antitumor activity by targeting mitochondrial complex II. Cell Death Dis. 2019;10:810.","journal-title":"Cell Death Dis"},{"key":"1016_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110851","volume":"110","author":"J Liao","year":"2023","unstructured":"Liao J, Qing X, Deng G, Xiao Y, Fu Y, Han S, et al. Gastrodin destabilizes survivin and overcomes pemetrexed resistance. Cell Signal. 2023;110:110851.","journal-title":"Cell Signal"},{"key":"1016_CR30","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.7150\/ijbs.25334","volume":"14","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Li M, Yu X, Liu T, Li T, Zhou L, et al. Butein suppresses hepatocellular carcinoma growth via modulating Aurora B kinase activity. Int J Biol Sci. 2018;14:1521\u201334.","journal-title":"Int J Biol Sci"},{"key":"1016_CR31","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.7150\/ijbs.37481","volume":"15","author":"W Liu","year":"2019","unstructured":"Liu W, Li W, Liu H, Yu X. Xanthohumol inhibits colorectal cancer cells via downregulation of Hexokinases II-mediated glycolysis. Int J Biol Sci. 2019;15:2497\u2013508.","journal-title":"Int J Biol Sci"},{"key":"1016_CR32","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7150\/ijbs.87180","volume":"20","author":"J Liao","year":"2024","unstructured":"Liao J, Qing X, Li X, Gan Y, Wang R, Han S, et al. TRAF4 regulates ubiquitination-modulated survivin turnover and confers radioresistance. Int J Biol Sci. 2024;20:182\u201399.","journal-title":"Int J Biol Sci"},{"key":"1016_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03434-z","volume":"12","author":"M Li","year":"2021","unstructured":"Li M, Liu H, Zhao Q, Han S, Zhou L, Liu W, et al. Targeting Aurora B kinase with Tanshinone IIA suppresses tumor growth and overcomes radioresistance. Cell Death Dis. 2021;12:152.","journal-title":"Cell Death Dis"},{"key":"1016_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2579-9","volume":"11","author":"M Li","year":"2020","unstructured":"Li M, Gao F, Zhao Q, Zuo H, Liu W, Li W. Tanshinone IIA inhibits oral squamous cell carcinoma via reducing Akt-c-Myc signaling-mediated aerobic glycolysis. Cell Death Dis. 2020;11:381.","journal-title":"Cell Death Dis"},{"key":"1016_CR35","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/s41420-023-01648-y","volume":"9","author":"L Xie","year":"2023","unstructured":"Xie L, Liao J, Liu W, Wang R, Li X, Li W, et al. Gastrodin overcomes chemoresistance via inhibiting Skp2-mediated glycolysis. Cell Death Discov. 2023;9:364.","journal-title":"Cell Death Discov"},{"key":"1016_CR36","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1142\/S0192415X23500957","volume":"51","author":"Z Zhou","year":"2023","unstructured":"Zhou Z, Han S, Liao J, Wang R, Yu X, Li M. Isoliquiritigenin Inhibits Oral Squamous Cell Carcinoma and Overcomes Chemoresistance by Destruction of Survivin. Am J Chin Med. 2023;51:2221\u201341.","journal-title":"Am J Chin Med"},{"key":"1016_CR37","doi-asserted-by":"crossref","unstructured":"Gan Y, Li X, Han S, Zhou L, Li W. Targeting Mcl-1 Degradation by Bergenin Inhibits Tumorigenesis of Colorectal Cancer Cells. Pharmaceuticals (Basel).2023;16:241.","DOI":"10.3390\/ph16020241"},{"key":"1016_CR38","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.molcel.2006.02.009","volume":"21","author":"U Maurer","year":"2006","unstructured":"Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell. 2006;21:749\u201360.","journal-title":"Mol Cell"},{"key":"1016_CR39","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/annonc\/mdx702","volume":"29","author":"WH Hsu","year":"2018","unstructured":"Hsu WH, Yang JC, Mok TS, Loong HH. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol. 2018;29:i3\u2013i9.","journal-title":"Ann Oncol"},{"key":"1016_CR40","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1021\/acs.jmedchem.6b00788","volume":"60","author":"PA Jackson","year":"2017","unstructured":"Jackson PA, Widen JC, Harki DA, Brummond KM. Covalent Modifiers: A Chemical Perspective on the Reactivity of \u03b1,\u03b2-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions. J Med Chem. 2017;60:839\u201385.","journal-title":"J Med Chem"},{"key":"1016_CR41","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.22.02186","volume":"41","author":"RS Herbst","year":"2023","unstructured":"Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023;41:1830\u201340.","journal-title":"J Clin Oncol"},{"key":"1016_CR42","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1021\/acs.jmedchem.1c00876","volume":"65","author":"M Shaikh","year":"2022","unstructured":"Shaikh M, Shinde Y, Pawara R, Noolvi M, Surana S, Ahmad I, et al. Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer. J Med Chem. 2022;65:1008\u201346.","journal-title":"J Med Chem"},{"key":"1016_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04685-0","volume":"13","author":"X Yu","year":"2022","unstructured":"Yu X, Zhou L, Liu W, Liu L, Gao F, Li W, et al. Skp2 stabilizes Mcl-1 and confers radioresistance in colorectal cancer. Cell Death Dis. 2022;13:249.","journal-title":"Cell Death Dis"},{"key":"1016_CR44","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s13046-024-03220-7","volume":"43","author":"J Liu","year":"2024","unstructured":"Liu J, Wei L, Miao Q, Zhan S, Chen P, Liu W, et al. MDM2 drives resistance to Osimertinib by contextually disrupting FBW7-mediated destruction of MCL-1 protein in EGFR mutant NSCLC. J Exp Clin Cancer Res. 2024;43:302.","journal-title":"J Exp Clin Cancer Res"},{"key":"1016_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06231-y","volume":"14","author":"MC Fitzgerald","year":"2023","unstructured":"Fitzgerald MC, O'Halloran PJ, Kerrane SA, N\u00ed Chonghaile T, Connolly NMC, Murphy BM. The identification of BCL-XL and MCL-1 as key anti-apoptotic proteins in medulloblastoma that mediate distinct roles in chemotherapy resistance. Cell Death Dis. 2023;14:705.","journal-title":"Cell Death Dis"},{"key":"1016_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04551-z","volume":"13","author":"YY Liang","year":"2022","unstructured":"Liang YY, Niu FY, Xu AA, Jiang LL, Liu CS, Liang HP, et al. Increased MCL-1 synthesis promotes irradiation-induced nasopharyngeal carcinoma radioresistance via regulation of the ROS\/AKT loop. Cell Death Dis. 2022;13:131.","journal-title":"Cell Death Dis"},{"key":"1016_CR47","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.steroids.2016.07.002","volume":"113","author":"X Zhang","year":"2016","unstructured":"Zhang X, Xue X, Zhao J, Guo Z, Ito Y, Sun W. Quantitative determination of gracillin by HPLC-MS\/MS after oral administration and its application to a pharmacokinetic study. Steroids. 2016;113:78\u201386.","journal-title":"Steroids"},{"key":"1016_CR48","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ijpharm.2006.09.025","volume":"330","author":"K Maiti","year":"2007","unstructured":"Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin\u2013phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharmaceutics. 2007;330:155\u201363.","journal-title":"Int J Pharmaceutics"},{"key":"1016_CR49","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00280-006-0355-x","volume":"60","author":"TH Marczylo","year":"2007","unstructured":"Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward WP, Gescher AJ. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol. 2007;60:171\u20137.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01016-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01016-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01016-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:06:27Z","timestamp":1785517587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01016-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1016"],"URL":"https:\/\/doi.org\/10.1038\/s41417-026-01016-9","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All animal procedures were approved by the Medical Research Animal Ethics Committee of Central South University (Changsha, China). All methods were performed in accordance with the relevant guidelines and regulations. This study did not involve human participants, human biological materials, or human data. Clinical trial number: not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}